AUTHORS
Sun-Hye Ko, MD, PhD, John Kuruvilla, MD2, Robert Puckrin, MD3, Neil Chua, MD4, Anthony Reiman, MD, SM5, Mona Shafey, MD6, Michael Crump, MD7, Tomohiro Aoki, MD, PhD8, Sita Bhella, MD9, Inna Y Gong, MD, PhD10, Robert Kridel, MD11, Vishal Kukreti, MD12, Anca Prica13, Abi Vijenthira, MD, MS14, Chloe Yang, MD15
AFFILIATIONS
1 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
2 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
3 Arthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, Alberta, Canada
4 Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
5 Department of Oncology, Saint John Regional Hospital, Horizon Health Network; School of Integrated Health, University of New Brunswick; Department of Medicine, Dalhousie University, all in Saint John, New Brunswick, Canada
6 Arthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, Alberta, Canada
7 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
8 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
9 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
10 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
11 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
12 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
13 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
14 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
15 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
ABSTRACT
Introduction
CD20×CD3 bispecific antibodies (BsAbs) are now standard of care options for relapsed/refractory non-Hodgkin lymphoma (NHL). Outcomes after BsAb progression and the prognostic value of reassessment at progression remain poorly defined.
Methods
We conducted a multicenter retrospective study of NHL patients treated with epcoritamab, glofitamab, or mosunetuzumab at five centers across three Canadian provinces from 2018 to 2025. Lymphomas were classified as aggressive (diffuse large B-cell lymphoma, mantle cell lymphoma, high-grade B-cell lymphoma, and transformed lymphoma) or indolent (follicular lymphoma, marginal zone lymphoma).
Overall survival (OS) and progression-free survival (PFS), measured from BsAb progression, were analyzed using Kaplan-Meier and Cox methods, with prognostic factors assessed at BsAb progression. Primary refractory disease was defined as progressive disease as the best response to BsAb; initial post-progression management was classified as active therapy, palliation, or observation. Trial-participation analyses included penalized Cox regression, competing-risks analysis, time-dependent Cox modeling, and a glofitamab-only analysis.
Results
Of 109 BsAb-treated patients, 55 with progression after BsAb were included (45 aggressive, 10 indolent). BsAb use differed by drug availability: epcoritamab was exclusively off-trial (20 aggressive, 1 indolent), mosunetuzumab was exclusively on-trial (6 aggressive, 4 indolent), and glofitamab was both off-trial (13 aggressive, 1 indolent) and on-trial (6 aggressive, 4 indolent). Median time to progression was 2.0 mo in aggressive and 12.4 mo in indolent lymphoma. ECOG PS ≥2 increased from 41.8% at BsAb initiation to 47.3% at progression, driven mainly by aggressive lymphoma (44.4% to 55.6%).
Post-progression outcomes were markedly worse in aggressive than indolent lymphoma (median PFS, 2.1 vs 41.2 mo; median OS, 3.3 vs 41.2 mo; both log-rank P<0.001). ECOG PS ≥2 at progression conferred inferior OS (overall: HR 4.28, P<0.001; aggressive: HR 2.54, P=0.007) and PFS (overall: HR 3.67, P<0.001; aggressive: HR 2.08, P=0.023). IPI ≥3 and stage IV at progression and prior CAR T-cell therapy in aggressive lymphoma were not associated with outcome. In aggressive lymphoma, primary refractory disease (35/45) was associated with inferior OS (HR, 2.49; 95% CI, 1.03-6.05; P=0.044) but not PFS (HR, 1.63; 95% CI, 0.77-3.43; P=0.202). Post-progression, 31 patients (56.4%) received active therapy, 22 (40.0%) received palliation, and 2 (3.6%) were observed. Active treatments included radiation (n=10), chemotherapy ± radiation (n=8), CAR T-cell therapy (n=5), trial (n=4), BsAb retreatment (n=3), and allogeneic transplantation (n=1).
In aggressive lymphoma, trial participation was associated with longer post-progression PFS (4.3 vs 2.0 mo; HR for non-trial vs trial, 3.23; 95% CI, 1.38-7.57; P=0.007) and numerically longer OS (8.5 vs 2.5 mo; HR, 2.20; 95% CI, 0.98-4.95; P=0.056). The OS association remained similar after Firth-type adjustment for baseline ECOG PS ≥2 and ≥3 prior lines (HR, 2.15; P=0.060). Subsequent-treatment initiation was similar by trial status (HR, 1.38; P=0.508), but non-trial patients had more pre-treatment deaths (HR, 6.79; P=0.013); fewer ultimately received active therapy (45.5% vs 75.0%) and more received palliation (54.5% vs 16.7%). Non-trial status remained associated with mortality after time-varying treatment adjustment (HR, 2.33; P=0.042) but attenuated after adjusting for a longer diagnosis-to-BsAb interval in trial patients (18.3 vs 11.9 mo; HR, 2.05; P=0.085), suggesting possible trial-selection effects. When restricted to glofitamab, the only BsAb used both on- and off-trial, trial status was associated with neither OS (HR, 1.01; P=0.991) nor PFS (HR, 1.36; P=0.586).
Forty-one (74.5%) died (37 aggressive, 4 indolent); 36 deaths were lymphoma-related (35 aggressive, 1 indolent) and 3 were infection-related (all indolent).
Conclusion
Outcomes post BsAb progression were poor in aggressive lymphoma. ECOG PS at progression was the most consistent prognostic marker, while primary refractory disease identified patients with inferior OS. Clinical trial-associated survival differences may reflect patient selection and timing effects and disease trajectory rather than a causal treatment benefit. Performance-status reassessment at progression post-BsAb may refine prognostic stratification and inform treatment planning.
DISCLOSURES
Sun-Hye Ko, MD, PhD: No relevant conflicts of interest to declare.